Format

Send to

Choose Destination
PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.

Machine learning models to predict disease progression among veterans with hepatitis C virus.

Author information

1
Michigan Medicine, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, Michigan, United States of America.
2
Department of Medicine, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA, United States of America.
3
VA Ann Arbor Health Services Research and Development Center of Clinical Management Research, Ann Arbor, Michigan, United States of America.
4
Department of Statistics, University of Michigan, Ann Arbor, MI, United States of America.
5
Michigan Medicine, Department of Internal Medicine, Division of Cardiology, Ann Arbor, Michigan, United States of America.
6
Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP), Ann Arbor, MI, United States of America.
7
Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, United States of America.
8
Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Healthcare System, Seattle, WA, United States of America.

Abstract

BACKGROUND:

Machine learning (ML) algorithms provide effective ways to build prediction models using longitudinal information given their capacity to incorporate numerous predictor variables without compromising the accuracy of the risk prediction. Clinical risk prediction models in chronic hepatitis C virus (CHC) can be challenging due to non-linear nature of disease progression. We developed and compared two ML algorithms to predict cirrhosis development in a large CHC-infected cohort using longitudinal data.

METHODS AND FINDINGS:

We used national Veterans Health Administration (VHA) data to identify CHC patients in care between 2000-2016. The primary outcome was cirrhosis development ascertained by two consecutive aspartate aminotransferase (AST)-to-platelet ratio indexes (APRIs) > 2 after time zero given the infrequency of liver biopsy in clinical practice and that APRI is a validated non-invasive biomarker of fibrosis in CHC. We excluded those with initial APRI > 2 or pre-existing diagnosis of cirrhosis, hepatocellular carcinoma or hepatic decompensation. Enrollment was defined as the date of the first APRI. Time zero was defined as 2 years after enrollment. Cross-sectional (CS) models used predictors at or closest before time zero as a comparison. Longitudinal models used CS predictors plus longitudinal summary variables (maximum, minimum, maximum of slope, minimum of slope and total variation) between enrollment and time zero. Covariates included demographics, labs, and body mass index. Model performance was evaluated using concordance and area under the receiver operating curve (AuROC). A total of 72,683 individuals with CHC were analyzed with the cohort having a mean age of 52.8, 96.8% male and 53% white. There are 11,616 individuals (16%) who met the primary outcome over a mean follow-up of 7 years. We found superior predictive performance for the longitudinal Cox model compared to the CS Cox model (concordance 0.764 vs 0.746), and for the longitudinal boosted-survival-tree model compared to the linear Cox model (concordance 0.774 vs 0.764). The accuracy of the longitudinal models at 1,3,5 years after time zero also showed superior performance compared to the CS model, based on AuROC.

CONCLUSIONS:

Boosted-survival-tree based models using longitudinal information are statistically superior to cross-sectional or linear models for predicting development of cirrhosis in CHC, though all four models were highly accurate. Similar statistical methods could be applied to predict outcomes in other non-linear chronic disease states.

PMID:
30608929
DOI:
10.1371/journal.pone.0208141
Free full text

Supplemental Content

Full text links

Icon for Public Library of Science
Loading ...
Support Center